
    
      Two cohorts of 6 healthy volunteers will be enrolled for the AME and absolute BA parts,
      respectively. The dose for both cohorts is 240 mg. The expected exposure of the dose is
      7-fold lower than the steady state reached in patients with castration-resistant prostate
      cancer.
    
  